

Product Data Sheet

Product Name: Nedosiran sodium

Cat. No.: GC70681

Chemical Properties

Cas. No. 2247026-22-6

Formula M.Wt 22183.6

Solubility H₂O : 100 mg/mL (4.51 mM; Need ultrasonic) Storage -20°C, sealed storage, away from moisture

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure

Nedosiran (sodium)

Background

Nedosiran sodium is a GalNAc-dsRNA conjugate designed to inhibit production of the hepatic lactate dehydrogenase (LDH) enzyme.

References:

- [1]. Kevin Shee, et al. Nedosiran Dramatically Reduces Serum Oxalate in Dialysis-Dependent Primary Hyperoxaluria 1: A Compassionate Use Case Report. Urology.2021 Oct;156:e147-e149.
- [2]. Gema Ariceta, et al. Hepatic Lactate Dehydrogenase A: An RNA Interference Target for the

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Treatment of All Known Types of Primary Hyperoxaluria. Kidney Int Rep.2021 Feb 3;6(4):1088-1098.
[3]. Thomas A Forbes, et al. Therapeutic RNA interference: A novel approach to the treatment of primary hyperoxaluria. Br J Clin Pharmacol.2021 May 22.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA